Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Search by expertise, name or affiliation
Contact Expert
View Scopus Profile
Min Yao, MD, MS, PhD
Professor
,
Department of Radiation Oncology
Penn State Cancer Institute
Cancer Institute, Next-Generation Therapies
h-index
4665
Citations
33
h-index
Calculated based on number of publications stored in Pure and citations from Scopus
2004
2025
Research activity per year
Overview
Fingerprint
Network
Research output
(117)
Similar Profiles
(6)
Fingerprint
Dive into the research topics where Min Yao is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Radiation Therapy
99%
Head and Neck Cancer
96%
Intensity Modulated Radiation Therapy
63%
Stereotactic Body Radiation Therapy
51%
Neoplasm
44%
Neck
42%
Head and Neck Squamous Cell Carcinoma
37%
Positron Emission Tomography
34%
Overall Survival
32%
Diseases
26%
Re-Irradiation
25%
Fluorodeoxyglucose
25%
Quality of Life
23%
Oncology
19%
Oropharynx Squamous Cell Carcinoma
18%
Chemoradiotherapy
18%
Cyberknife
17%
Cisplatin
16%
Squamous Cell Carcinoma
16%
Recurrent Disease
15%
Nasopharynx Carcinoma
15%
Neck Dissection
14%
Proton Therapy
14%
Clinical Trial
13%
Larynx
12%
Lung Cancer
11%
Surgery
10%
Cancer
10%
Cetuximab
10%
Metastatic Carcinoma
10%
Oral Cavity
10%
Lymph Node
10%
Primary Tumor
9%
Adverse Event
9%
Distant Metastasis
9%
Positron Emission Tomography-Computed Tomography
9%
Fluorodeoxyglucose F 18
8%
Treatment Planning
8%
Cancer of Unknown Primary Origin
8%
Thoracic Wall
7%
Cesium 131
7%
Rib
7%
Monte Carlo Method
7%
Brachytherapy
7%
Cohort Analysis
7%
Radiation Treatment Planning
7%
Wart Virus
6%
Standardized Uptake Value
6%
Keyphrases
Head-and-neck Cancer
100%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
56%
Intensity-modulated Radiotherapy
41%
Radiation Therapy
34%
Intensity-modulated Radiation Therapy
34%
Overall Survival
33%
Radiotherapy
32%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
31%
Head-and-neck
29%
Re-irradiation
29%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
26%
Locally Advanced
25%
Stereotactic Body Radiotherapy
25%
Stereotactic Body Radiation Therapy
24%
Tumor
18%
CyberKnife
17%
Nasopharyngeal Carcinoma
16%
Cisplatin
16%
High-risk Human Papillomavirus (HR-HPV)
15%
Chemoradiotherapy
15%
Neck Dissection
14%
Positron Emission Tomography
14%
Squamous Cell Carcinoma of Head
13%
Distant Metastasis
12%
Phase II Study
12%
Cancer Patients
12%
Treatment Plan
11%
Progression-free Survival
11%
Radiation Dose
11%
NRG Oncology
11%
Proton Beam Therapy
10%
Non-resectable
10%
Cetuximab
10%
Chemoradiation
10%
High Risk
9%
Organs at Risk
9%
P16+
9%
Deformable Image Registration
9%
Chemotherapy
9%
Positron Emission Tomography-computed Tomography (PET-CT)
9%
Failure Pattern
9%
Post-radiotherapy
9%
Regional Failure
8%
Metastasis
8%
Definitive Radiation
8%
American College of Radiology Appropriateness Criteria
8%
Docetaxel
7%
Intraoperative Radiation Therapy
7%
Radiation Treatment Planning
7%
University of Iowa
7%
